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receptors and their ligands suggests the surface
electrostatic potential of the co-receptor to be a
key player in the HIV-1 tropism
Olga V Kalinina*, Nico Pfeifer and Thomas LengauerAbstract
Background: CCR5 and CXCR4 are the two membrane-standing proteins that, along with CD4, facilitate entry of
HIV particles into the host cell. HIV strains differ in their ability to utilize either CCR5 or CXCR4, and this specificity,
also known as viral tropism, is largely determined by the sequence of the V3 loop of the viral envelope protein
gp120.
Results: With statistical and docking approaches we have computationally analyzed binding preferences of CCR5
and CXCR4 to both V3 loop sequences of virus strains of different tropism and endogenous ligands.
Conclusions: We conclude that the tropism cannot be satisfactorily explained by amino-acid interactions alone,
and suggest a two-step mechanism, by which initial coreceptor selection and approach of the ligand to the binding
pocket is dominated by charge and glycosylation pattern of the viral envelope.
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To enter a host cell, the HIV envelope protein gp120
binds to the cellular CD4 receptor and to one of the two
cellular co-receptors, CCR5 or CXCR4. We call viruses
(or their genome sequences) that can bind exclusively to
CCR5 R5-tropic, those that can bind exclusively to
CXCR4 X4-tropic and those that can bind to either cor-
eceptor dual-tropic viruses. X4 and dual-tropic viruses
together form the set of X4-capable viruses. Both CCR5
and CXCR4 belong to a prominent family of G-protein
coupled receptors. They bind to chemokines: CCR5
binds to a number of inflammatory CC-chemokines in-
cluding CCL3, CCL4 and CCL5 [1,2], CXCR4 is a recep-
tor for SDF-1 [3] and extracellular ubiquitin [4]. Viral
usage of one or the other coreceptor can vary, and is of
pivotal importance for the correct choice of antiviral
therapy with a class of drugs called entry inhibitors. The
first CCR5 inhibitor, maraviroc, has entered clinical* Correspondence: kalinina@mpi-inf.mpg.de
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reproduction in any medium, provided the orpractice in the year 2007 [5], but no inhibitor of CXCR4
is on the market yet. Since an entry inhibitor targeting
CCR5 or CXCR4, respectively, can only be effective
against viruses with the corresponding tropism, adminis-
tering entry inhibitors, such as maraviroc, requires an
advance test of viral tropism. There are two classes of
such tests: phenotypic and genotypic. In phenotypic
tests, viral tropism is determined in a laboratory assay.
In genotypic tests the viral tropism is inferred from the
relevant regions of the viral genome by computational
means. Several computational prediction models based
on the sequences of a part of the gp120 sequence called
the V3 loop have been proposed [6-9]. Even though re-
cently a genotypic test has become available that points
to regions in the V3 loop determining tropism [10], nei-
ther class of tests provides a mechanistic understanding
of the coreceptor choice. In this study, various methods
of computational structural biology have been applied to
elucidate this mechanism.
To date, only an experimentally resolved structure of
nearly full-length gp120 with a short N-terminal peptidel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recently in a modeling attempt to understand the mech-
anistic basis of viral tropism [12]. In contrast, we have
studied interactions between V3 loop and the full-length
co-receptor.
Results
Structural analysis of V3 loops corresponding to different
virus subtypes does not reveal any tropism preferences
In our study, we used two sets of V3 loop sequences:
one set of 7 R5-tropic and 13 X4-capable sequences with
experimentally verified tropism [10] and another set of
47 R5-tropic and 49 X4-capable sequences with tropism
predicted using geno2pheno-C_NGS-Sanger [8] (see
Methods for more details).
The net charge of V3 loop sequences from the set of
experimentally verified cases is significantly higher for
X4-capable sequences than for R5-tropic sequences
(Figure 1a). However, this may be a consequence of a
bias during selection of sequences for experimental
testing. The set of sequences with predicted tropism
is more diverse and evenly distributed in sequence
space than the sequences with experimentally verified
tropism: the median and 1st and 3rd quartiles of the
pairwise sequence identity are 0.76, 0.71, 0.79 for the
predicted R5-tropic; 0.88, 0.88, 0.92 for the experi-
mentally verified R5-tropic; 0.60, 0.68, 0.74 for the
predicted X4-capable; and 0.65, 0.71, 0.76 for the ex-
perimentally verified X4-capable sequences. The differ-
ence of the sequence charge between the two tropism
types for the predicted sequences is not very pronounced,
although significant, and the median charge is equal for
R5-tropic and X4-capable sequences. There is no signifi-
cant correlation between the net charge of the V3 loop
and the probability of exhibiting the X4-capable pheno-
type, as calculated by geno2pheno-C_NGS-Sanger [8]
(p-values −0.17 and 0.25 for R5-tropic and X4-capable
sequences, respectively, Figure 1b).
PepSite is a computational tool that scans the surface
of a given protein for patches that are likely to bind indi-
vidual amino acid residues or peptides up to ten amino
acids [13,14], providing a score that reflects the propen-
sity of the peptide to bind to the protein. The PepSite
score is expressed in relative units and the higher scores
mean better binding. We apply PepSite in a sliding win-
dow of 10 residues to assess the binding of the experi-
mentally verified X4-capable and R5-tropic sequences to
CXCR4, and acquire higher average scores for the X4-
capable sequences (Figure 2A, low statistical significance
here is due to the limited size of the sample). The same
procedure for the sequences of the predicted set does
not reveal such a trend (Figure 2B). Still, both experi-
mentally verified and predicted X4-capable sequences
have significantly higher propensity to bind to CCR5than to CXCR4 (p-value 0.064 for experimentally tested
and 6.156*10-08 for predicted sequences based on a two-
sided Wilcoxon test). None of the X4-capable sequences
has a score for CXCR4 binding that would exceed the
score for CCR5 binding by more than 1.5 percentage
points. This may indicate that these viruses are equally
capable of using both CCR5 and CXCR4 for entry. For
R5-tropic sequences, on the contrary, we find a statisti-
cally significant higher propensity to bind to CCR5 ra-
ther than to CXCR4 in both experimentally verified and
predicted sequence sets, in agreement with the assigned
phenotype.
Both CCR5 and CXCR4 belong to GPCR family of
transmembrane proteins and have seven transmembrane
helices (Figure 3a). In the crystal structure, CXCR4 is
bound to an inhibitor peptide (magenta in Figure 3a)
that penetrates deeply into the extracellular pocket of
the receptor. The hotspots for individual amino acids
are predominantly places inside this pocket, as well. Pro-
line residues are most favorably placed deeply inside the
pocket (magenta in Figure 3c), which suggests that the
β-hairpin structure of the V3 loop penetrates deeply into
the binding pocket of the coreceptor [15]. Aromatic resi-
dues are more highly preferred along the channel, and
charged residues are situated near the mouth of the
pocket (Figure 3c). These preferences are not as pro-
nounced in the CCR5 model as in the structure of
CXCR4 (data not shown).
The docking experiment was unable to differentiate
between X4-capable and R5-tropic sequences when they
were placed into the pocket of CXCR4. The docking
energies (FlexPepDock [16] energy scores between −25
and −40 for interface energy and −120 and −280 for
whole-complex energy) and the docking poses of the
whole loop and its parts do not significantly differ between
the sequences of the two tropisms neither in the set of
experimentally verified, not in the set of sequences
with predicted tropism. Without more experimental
information on the precise positioning of the V3 loop
in the binding pocket of the coreceptor, it is probably
impossible to model this interaction to anything ap-
proaching atomic detail. The structural bioinformatics
approaches fail to further explain the process of core-
ceptor binding.
Structural comparison of the CCR5 and CXCR4 chemokine
receptors
CCR5 and CXCR4 are chemokine receptors of the G-
protein coupled receptor family, with a global sequence
identity of 33%. CXCR4 was recently crystallized as a
dimer [15], and it is reported to dimerize in cells inde-
pendent of ligand binding [17]. The structure forms a
large pocket on the extracellular side where the ligand
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Figure 1 (See legend on next page.)
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Figure 1 Charge of V3 loop sequences. a. Charges of the V3 loops of experimentally tested sequences (exp) and sequences predicted to be
prototypic for their tropism (pred). The box plots show median, first and third quartile ±1.5 interquartile range. P-values displayed are based on a
two-sided Wilcoxon test. b. Dot-plots showing the relationship between the net charge of the V3 loop and the probability of the corresponding
strain to show the X4-capable phenotype, as calculated by geno2pheno-C_NGS-Sanger [8], for the set of predicted sequences. P-values based on
Pearson’s product–moment correlation test: -0.17 for R5-tropic and 0.25 for X4-capable sequences.
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been experimentally resolved, so we have modeled it
using a CXCR4 structure (PDB entry 3oe0) as a tem-
plate. The model checks out as acceptable when tested
with PROCHECK [18].
Despite their high sequence identity and hence struc-
tural similarity, the surface electrostatic potentials of the
two receptors differ substantially (Figure 4): the binding
pocket of CXCR4 and the area near its mouth are nega-
tively charged, while CCR5 has a negatively charged
pocket and a neutral to positive entrance to that pocket.
The N-terminus that bears a significant negative charge
due to sulfation [19,20] is disordered and absent from
both structures.
Comparison of endogenous ligands
Both CCR5 and CXCR4 are chemokine receptors. CCR5
binds to a variety of CC-chemokines including CCL5, as
well as CCL3 and CCL4 [1,2]. The ligands of CXCR4 are
SDF-1 [3] and extracellular ubiquitin [4]. When structur-
ally compared using DaliLite [21], CCL5, CCL4 and
CCL3 exhibit significant structural similarity but little,
while still detectable, resemblance to the CXCR4 ligand
SDF-1 (Figure 5). CXCR4 ligands exhibit no structural
similarity among each other. There is no structural simi-
larity between endogenous ligands of CCR5 or CXCR4
and the structure of the V3 loop as it is crystallized in















Figure 2 PepSite scores of V3 loop sequences. PepSite scores for a 10-a
X4-capable sequences to bind to CXCR4. A: experimentally verified sequen
two-sided Wilcoxon test.The electrostatic potentials of the ligands are largely
compatible with the electrostatic potential of the recep-
tors: CCL3 and CCL4 have negatively charged surfaces,
CCL5, although generally positive, is glycosylated [22],
hence potentially it can inherit a negative charge from the
glycan. SDF-1, in contrast, has a positive potential on the
surface, while ubiquitin is generally neutral (Figure 6).
Analysis of patterns of glycosylation in R5-tropic and
X4-capable sequences
We have analyzed the distribution of potential glycosyla-
tion sites in R5-tropic and X4-capable sequences. For
the dataset of experimentally verified sequences, all R5-
and all but two X4-capable sequences contain such a
glycosylation site at position 301 (predicted with N-
GlycoSite [23]). Of the predicted sequences, all R5-
tropic and all but three X4-capable sequences contain
this site. This glycosylation site has been proven to be
crucial for coreceptor tropism: its removal switches the
virus to use CXCR4 [24]. Yet, this site appears to be
present in many X4-capable sequences, but it is impos-
sible to assess the extent of its occupancy by computa-
tional tools.
There are two other potential glycosylation sites just
downstream of the V3 loop at positions 332 and 339.
For a larger set of 199 sequences from a study on
HIV neutralization by combination of monoclonal















mino acid sliding window reflect the propensities of R5-tropic and
ces; B: predicted sequences. P-values displayed are based on a
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Figure 3 Structural features of the coreceptor. a. Overall view of the coreceptor. The CXCR4 polypeptide is shown in green, lysozyme
(fused to assist crystallization) is shown in orange, the inhibitor peptide in magenta. The amino acids in contact with the inhibitor peptide are
shown in cyan and in surface representation. The approximate position of the membrane is shown as gray rectangles (not in crystal structure).
b. Cross-section and close-up of the pocket. Colors as in panel a. c. PepSite hotspots for amino acid binding on the coreceptor surface. Hotspots
for binding of individual amino acids in the pocket of CXCR4 (alanine: salmon; cysteine: cyan; glutamate and aspartate: red; phenylalanine,
tryptophan, tyrosine: gray; glycine: orange; histidine: light gray; isoleucine, leucine, valine: yellow; arginine, lysine: blue; methionine: light orange;
asparagine, glutamine: green; proline: magenta; serine, threonine: purple). CXCR4 is rendered transparent for clarity.
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(Figure 7, tropism predicted with geno2pheno [core-
ceptor] [6] at 10% false positive rate cutoff ). For the
position 301, the association with tropism type is sta-
tistically significant by Fisher’s exact test (p-value
7.64e-06, Bonferroni corrected p-value: 0.0013). Almost
all R5-tropic sequences have a glycosylation site at pos-
ition 301, as opposed to about 80% of X4-capable se-
quences. Positions 332 and 339 contain a glycosylation
site in 70% to 80% of R5- and 50 to 60% of X4-tropic
sequences.
Discussion
We have analyzed binding preferences of the V3 loops of
HIV strains of different tropism. PepSite, pursuing a stat-
istical approach, clearly indicates binding of the V3 loop
inside the pocket of the co-receptor, but is unable to dis-
criminate between R5- and X4-tropism satisfactorily.
Docking also fails to discriminate between the two kinds
of tropism. Based on our analysis, we can propose that
V3 loops with both kinds of tropism, once placed inside
the binding pocket of either coreceptor, would bind
comparably tightly.
However, the electrostatics is strikingly different be-
tween CXCR4 and CCR5. The electrostatics of their
cognate ligands suggests that electrostatic interactions
play an important role in the endogenous recognition
process [15]. We propose a two-step model of the
binding process, in which the first step is characterizedby a long-range electrostatic interaction between a cor-
eceptor and its ligand. A suitable potential may pre-
clude the initial contact between the co-receptor and
the virus of the non-cognate tropism. This model is
consistent with the general two-step model for ligand-
receptor recognition, which states that long-range electro-
static interactions govern the formation of non-specific
encounter complex, and then binding partners reorient
themselves to increase the complementarity of the sur-
faces [26].
Charge has long been recognized to differ between
R5-tropic and X4-capable V3 loop sequences [27],
and mutation of neutral to positively charged, or nega-
tively charged to neutral amino acids can switch the virus
to using CXCR4 [28]. This may explain the fact that the
charge of the V3 loop is a reasonable predictor for virus
tropism [29], but not a perfect one. Machine-learning
based classifiers improve the prediction [6-9]. Indeed,
although the net charge of the V3 loop sequences
predicted to be prototypic for their tropism differs
significantly between the tropism classes, it cannot ac-
count for the entire phenomenon of tropism (Figure 1).
We can hypothesize that, although the contribution of the
charge is important for the determination of tropism,
other factors, such as post-translational modifications,
may play a role.
Both CCR5 and CXCR4 are extensively post-translationally
modified in their extracellular part; however, most of these





Figure 4 Surface electrostatic potential of the coreceptors. Electrostatic potential for structures of CCR5 (modelled) and CXCR4 (modified
from PDB entry 3oe0) calculated with ABPS [36]. Red corresponds to a potential of −5 kT/e; blue, 5 kT/e.
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N-terminus is characteristic for both proteins [19,20].
The sulfation is critical for interaction between HIV
gp120 and CCR5 [30], but not so much for CXCR4
[31]. If the negative N-terminus plays some role in
the binding of the more highly conserved base of the
V3 loop, which seems plausible by its position on top
of the pocket mouth, it can be compensated for by
the more negative charge of the pocket entrance of
CXCR4. Differential N-glycosylation within the N-
terminus of CXCR4 also alters the ability of CXCR4
to bind R5-tropic viruses, but this could not be inves-
tigated in the context of the presented study.As many viral envelope proteins, gp120 is heavily gly-
cosylated, and glycosylation is known to play an import-
ant role in viral tropism. Limited evidence in the
literature [23,32,33] suggests that R5-tropic viruses tend
to be more heavily glycosylated, and the glycans tend to
exhibit more complex branching patterns and to be sia-
lylated more frequently, which equips them with nega-
tive charge. Removal of a glycosylation site at position
301 leads to an unambiguous switch of tropism from
R5 to X4 [24]. Since the exact extent to which every
single potential glycosylation site is occupied is not
known, structural modeling appears to be inappropri-
ate in this case. However, we observe a statistically
Figure 5 Structural similarity of endogenous ligands of CCR5 and CXCR4. Each cell presents a structural alignment of two ligands (one
shown in green and the other in magenta; for clarity, only alignment of the first chain of the structures of each ligand is shown). The comparison
was performed with DaliLite [21], the obtained Z-scores, RMSD (root-mean-square deviation) of Cα atoms, number of aligned residues, and
percent of the identical residues in the alignment are reported in each cell.
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sites in R5-tropic than in X4-capable sequences, pos-
ition 301 being the most prominent case. Although
the trend is pronounced, there remains a large frac-
tion of X4-capable sequences with the glycosylation
sites at the positions mentioned above. Not necessar-
ily all these sites are occupied. The known consensus
for N-linked glycosylation is rather degenerate (NXT
where X is any amino acid except proline). There
might be a more complicated, yet unknown, sequence
signal that determines glycosylation of 301 N, which
assures that R5-tropic sequences are glycosylated
more often than X4-capable sequences, or that this
glycan is more highly branched and/or more fre-
quently sialylated (which would increase its negative
charge) In summary, we hypothesize that differential
glycosylation of the HIV envelope gp120 protein isan important factor for choice of co-receptor, and this
choice is primarily guided by the V3 loop charge, either
defined by the sequences, or conferred by glycosylation.
Conclusions
We propose a two-step model of interaction between
the V3 loop of the HIV Env protein and the CCR5 or
CXCR4 coreceptor of the host cell. The choice of the
coreceptor is determined at an initial stage by the
charge of the V3 loop. We hypothesize that differen-
tial glycosylation of HIV envelope gp120 protein is an
important factor for choice of co-receptor, as it may
alter the charge. This model explains well the avail-
able data on the importance of charged residues at
certain positions of the V3 loop, as well as the ob-






Figure 6 Surface electrostatic potential of endogenous ligands. The calculation and the display features are identical to the ones used
in Figure 4.
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Experimentally verified V3 loop sequences were re-
trieved from [10]. As described in [10], viruses were de-
rived from blood samples of HIV-1 infected patients,
cultivated in a cell line, and the SI/NSI phenotype was
determined by light microscopy. The dataset consists of
7 R5-tropic and 13 X4-tropic sequences.
A set of V3 loop sequences prototypic for each trop-
ism type was obtained with the tropism prediction tool
geno2pheno-C_NGS-Sanger [8]. This data set was con-
structed by predicting coreceptor usage using the
coreceptor prediction method introduced in [8] on
the Sanger sequences of data from the MOTIVATE aswell as the 1029 trial (see [8] for more details on the
data set). The sequences were ordered by predicted
risk of X4 emergence and the most extreme 47 (risk
of X4 emergence smaller than 27.2%) and 49 (risk of
X4 emergence larger than or equal to 50%) sequences
were selected. The sequences of the second group are
predicted to be able to use CXCR4 as the coreceptor
(X4-capable), whereas the sequences of the first group
are incapable of using CXCR4 and can bind only to
CCR5 (R5-tropic). This does not exclude that the se-
quences in the group of the X4-capable viruses can use
CCR5 as well. The new prediction tool geno2pheno-
C_NGS-Sanger [8] does not report FPR (false positive
Figure 7 Predicted glycosylation profile of the V3 loop sequences. The X-axis shows the positions along the V3 loop (numbering of the
whole-length gp120); the Y-axis, the relative frequency of occurrence of a potential glycosylation site (predicted with N-GlycoSite [23]) in the
dataset from [25].
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corresponding virus strain is capable of using CXCR4
(cut-offs mentioned above). In an additional analysis,
we predicted the FPR for these sequences using the
original tool geno2pheno[coreceptor] and only kept
sequences, for which both tools agreed on the trop-
ism call (10% FPR as recommended by the European
guidelines [34]). We achieved similar results with this
sequence subset (data not shown).
An experimentally resolved three-dimensional struc-
ture of CXCR4 (PDB entry 3oe0, [15]) was edited to re-
move the portion corresponding to T4 lysozyme that
was fused to facilitate crystallization. This structure was
also used as a template for building a homology model
of the CCR5 structure with MODELLER [35] (sequences
of CXCR4 and CCR5 have 33% identical and 55% similar
amino acids). Preferential peptide localization was calcu-
lated using PepSite [14]. Electrostatic potentials were
calculated using ABPS [36]. The structural comparison
of the endogenous receptor ligands was performed using
the DaliLite web server [21].
All sequences of the V3 loop under consideration were
modeled onto the structure of the V3 loop extracted
from the PDB entry 2b4c by introducing amino acid
mutations using FoldX [37]. Only sequences of thesame length as in the template structure were used
for modeling, hence 17 experimentally verified se-
quences (7 R5- and 10 X4-tropic) and 72 sequences
with predicted tropism (28 R5- and 44 X4-tropic)
were modeled. Docking was performed using FlexPep-
Dock protocol [16], a peptide-protein docking proto-
col with a fully flexible peptide, of the Rosetta modelling
suite [38]. The 25 best-scoring modelled structures
were considered for each complex. The charge of V3
loops was calculated using Protein Calculator v.3.3
[39]. This tool is not applicable to folded proteins,
but due to its high structural flexibility, the V3 loop
can be regarded as a flexible peptide.
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While this manuscript was under peer review, an X-ray structure of human
CCR5 in complex with maraviroc was resolved at 2.7 Å [40] (PDB id 4MBS).
It supports the model proposed here in several respects:
(i) The structure of the protein is very similar to our model (1.15 Å all atom
RMSD over 278 amino acids, which covers the whole CCR5 protein except
the inserted rubredoxin).
(ii) The electrostatic surface potential is also observed to differ between
CXCR4 and CCR5 [40], thus supporting our two-step binding model.
(iii) The position of maraviroc in the extracellular pocket coincides with the
position of the tip of the V3 loop proposed here.
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